Academic literature on the topic 'HIV vaccine; adjuvants'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'HIV vaccine; adjuvants.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "HIV vaccine; adjuvants"
Berendam, Stella J., Papa K. Morgan-Asiedu, Riley J. Mangan, Shuk Hang Li, Holly Heimsath, Kan Luo, Alan D. Curtis, et al. "Different adjuvanted pediatric HIV envelope vaccines induced distinct plasma antibody responses despite similar B cell receptor repertoires in infant rhesus macaques." PLOS ONE 16, no. 12 (December 31, 2021): e0256885. http://dx.doi.org/10.1371/journal.pone.0256885.
Full textMoser, B. A., R. C. Steinhardt, Y. Escalante-Buendia, D. A. Boltz, K. M. Barker, B. J. Cassaidy, M. G. Rosenberger, S. Yoo, B. G. McGonnigal, and A. P. Esser-Kahn. "Increased vaccine tolerability and protection via NF-κB modulation." Science Advances 6, no. 37 (September 2020): eaaz8700. http://dx.doi.org/10.1126/sciadv.aaz8700.
Full textKozlowski, Pamela A., and Anna Aldovini. "Mucosal Vaccine Approaches for Prevention of HIV and SIV Transmission." Current Immunology Reviews 15, no. 1 (April 12, 2019): 102–22. http://dx.doi.org/10.2174/1573395514666180605092054.
Full textLouis, Lumena, Megan C. Wise, Hyeree Choi, Daniel O. Villarreal, Kar Muthumani, and David B. Weiner. "Designed DNA-Encoded IL-36 Gamma Acts as a Potent Molecular Adjuvant Enhancing Zika Synthetic DNA Vaccine-Induced Immunity and Protection in a Lethal Challenge Model." Vaccines 7, no. 2 (May 22, 2019): 42. http://dx.doi.org/10.3390/vaccines7020042.
Full textOzorowski, Gabriel, Albert Cupo, Michael Golabek, Michelle LoPiccolo, Thomas A. Ketas, Matt Cavallary, Christopher A. Cottrell, P. J. Klasse, Andrew B. Ward, and John P. Moore. "Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP TrimersIn Vitro." Journal of Virology 92, no. 13 (April 18, 2018): e00381-18. http://dx.doi.org/10.1128/jvi.00381-18.
Full textGupta, Sachin, Emily S. Clark, James M. Termini, Justin Boucher, Saravana Kanagavelu, Celia C. LeBranche, Sakhi Abraham, David C. Montefiori, Wasif N. Khan, and Geoffrey W. Stone. "DNA Vaccine Molecular Adjuvants SP-D-BAFF and SP-D-APRIL Enhance Anti-gp120 Immune Response and Increase HIV-1 Neutralizing Antibody Titers." Journal of Virology 89, no. 8 (January 28, 2015): 4158–69. http://dx.doi.org/10.1128/jvi.02904-14.
Full textCeglia, Valentina, Sandy Zurawski, Monica Montes, Aurelie Bouteau, Zhiqing Wang, Jerome Ellis, Mitchell Kroll, Botond Z. Igyarto, Yves Levy, and Gerard Zurawski. "Dendritic cell targeting anti-CD40 antibody-CD40L-HIV-1 vaccines are adjuvant intrinsic." Journal of Immunology 204, no. 1_Supplement (May 1, 2020): 167.2. http://dx.doi.org/10.4049/jimmunol.204.supp.167.2.
Full textBui, Cac T., Lisa M. Shollenberger, Yvonne Paterson, and Donald A. Harn. "Schistosoma mansoni Soluble Egg Antigens Enhance Listeria monocytogenes Vector HIV-1 Vaccine Induction of Cytotoxic T Cells." Clinical and Vaccine Immunology 21, no. 9 (July 2, 2014): 1232–39. http://dx.doi.org/10.1128/cvi.00138-14.
Full textShollenberger, Lisa M., Stephanie K. Norwood, and Zachary J. Bement. "Development of alternative vaccination strategies to overcome Tc1 vaccine failure caused by chronic schistosomiasis." Journal of Immunology 204, no. 1_Supplement (May 1, 2020): 167.13. http://dx.doi.org/10.4049/jimmunol.204.supp.167.13.
Full textVijayan, Mohapatra, Uthaman, and Park. "Recent Advances in Nanovaccines Using Biomimetic Immunomodulatory Materials." Pharmaceutics 11, no. 10 (October 14, 2019): 534. http://dx.doi.org/10.3390/pharmaceutics11100534.
Full textDissertations / Theses on the topic "HIV vaccine; adjuvants"
Hanson, Melissa C. (Melissa Catherine). "Enhancement of HIV vaccine efficacy via lipid nanoparticle-based adjuvants." Thesis, Massachusetts Institute of Technology, 2014. http://hdl.handle.net/1721.1/97975.
Full textCataloged from PDF version of thesis. "December 2014."
Includes bibliographical references (pages 93-108).
Adjuvants are immunomodulators and/or formulations/delivery vehicles which enhance immune responses to vaccines. The lack of progress in the development of an HIV humoral vaccine is due, in part, to the absence of available adjuvants which can be sufficiently potent with minimal adverse side effects. The main goal of this thesis was to develop nanoparticles as HIV vaccine adjuvants. Building upon previous work in the Irvine lab, we determined the potency of lipid-coated microparticles was due in part to the in situ generation of antigen-displaying liposomes. Synthetic liposomes were nearly as potent as lipid-coated microparticles, but with a 10-fold greater antigen conjugation efficiency. We subsequently optimized unilamellar liposomes as delivery vehicles for surface-displayed HIV antigens. For vaccines with a recombinant gpl20 monomer (part of the HIV envelope trimer), immunization at 0 and 6 weeks with 65 nm or 150 nm diameter liposomes with 7.5 pmol gpl20 was found to induce strong anti-gp120 titers which competed with the broadly-neutralizing antibody VRC01. The second HIV antigen used was a peptide derived from the membrane proximal external region (MPER) of the gp41 protein. High-titer IgG responses to MPER required the presentation of MPER on liposomes and the inclusion of molecular adjuvants such as monophosphoryl lipid A. Anti-MPER humoral responses were further enhanced optimizing the MPER density to a mean distance of -10-15 nm between peptides on the liposomes surfaces. Lastly, we explored the adjuvant potential of cyclic dinucleotides (CDNs) with MPER liposome vaccines. Encapsulation of CDN in PEGylated liposomes enhanced its accumulation in draining lymph nodes (dLNs) 15-fold compared to unformulated cyclic dinucleotide. Liposomal CDN robustly induced type I interferon in dLNs, and promoted durable antibody titers comparable to a 30-fold larger dose of unformulated CDN without the systemic toxicity of the latter. This work defines several key properties of liposome formulations that promote durable, high-titer antibody responses against HIV antigens and demonstrates the humoral immunity efficacy of nanoparticulate delivery of cyclic dinucleotides, which is an approach broadly applicable to small molecule immunomodulators of interest for vaccines and immunotherapy.
by Melissa C. Hanson.
Ph. D.
Buglione-Corbett, Rachel. "Adjuvant-Specific Serum Cytokine Profiles in the Context of a DNA Prime-Protein Boost HIV-1 Vaccine: A Dissertation." eScholarship@UMMS, 2013. https://escholarship.umassmed.edu/gsbs_diss/666.
Full textBuglione-Corbett, Rachel. "Adjuvant-Specific Serum Cytokine Profiles in the Context of a DNA Prime-Protein Boost HIV-1 Vaccine: A Dissertation." eScholarship@UMMS, 2004. http://escholarship.umassmed.edu/gsbs_diss/666.
Full textBraga, Catarina Joelma Magalhães. "Pesquisa de novos adjuvantes para vacinas terapêuticas." Universidade de São Paulo, 2011. http://www.teses.usp.br/teses/disponiveis/42/42132/tde-13022012-080631/.
Full textThe search for adjuvants that are able to stimulate an efficient cellular immune response represents an important contribution in vaccine development. In this study, we evaluated the potential of Salmonella flagellin as adjuvant for activation of T lymphocytes, with emphasis on the activation of CD8+ T cells, on the mice immunized with different approaches such as vaccines based on attenuated Salmonella strains; acellular vaccines with purified flagellin co-administered or genetically fusioned to the target antigen; or even DNA vaccines. Our results demonstrate that the use of flagellin in the form of DNA vaccines induced greater therapeutic protection than the same formulation used in the form of subunit vaccines, suggesting that the adjuvant effects of flagellin to the activation of CTLs are related not only to link to TLR5. The results presented in this work contribute significantly to the understanding of the mechanisms of flagellin adjuvanticity, particularly in the context of activation of responses mediated by T cells.
Gutjahr, Alice. "Évaluation de combinaisons de ligands de PRR et de particules biodégradables pour la vaccination muqueuse." Thesis, Lyon, 2017. http://www.theses.fr/2017LYSE1325.
Full textThere are many barriers to the development an effective HIV vaccine. The use of adjuvants is a promising option to overcome these obstacles. In this context, the objective of this PhD is the evaluation of combinations of PRR ligands and biodegradable particles for mucosal vaccination.The first part of this study aimed at assessing the added value of hybrid molecules composed of two PRR ligands compared to the co-administration of the two agonists. TLR7 and TLR2 stimulating molecules followed by TLR7 and NOD2 were evaluated. We demonstrated the interest of the association of PRR ligands within the same molecule for the induction of systemic and mucosal immune responses.Recent studies showed the interest of STING agonists as a vaccine adjuvant. We investigated the induction of immune responses by STING agonists administered parenterally or mucosally. We confirmed the strong potential of STING ligands for the induction of cellular and mucosal responses.In these studies, we demonstrated that the interest of vectorization of PRR agonists depends on the molecule. Indeed, although the encapsulation of a TLR7/TLR2 hybrid molecule has no impact on the induced immune response, the vectorization of STING agonists potentiates their immunostimulatory effect.Finally, we showed that the route of administration has an impact on the immune response induced. In order to better understand the mechanisms involved, a biodistribution study of PLA NP formulations after systemic or mucosal administration was performed
Xu, Lin. "HIV-1 mucosal immunity : from infection to prevention : HIV-1 envelope gp41 conserved region P1 modulates the mucosal innate immune response and acts as a potential mucosal adjuvant The HIV-1 viral synapse signals human foreskin keratinocytes to secrete thymic stromal lymphopoietin facilitating HIV-1 foreskin entry By shaping the antigen binding site in IgA, the CH1α domain is crucial for HIV-1 protection in highly exposed sero-negative individuals The antigen HIV-1 envelope gp41 conserved region P1 can act as mucosal adjuvant by modulating the innate immune response." Thesis, Sorbonne Paris Cité, 2018. http://www.theses.fr/2018USPCB071.
Full textMucosal vaccination, especially intranasal administrated ones, has been considered to be ideal for protection from pathogens invading through mucosal sites. However, the lack of specific adjuvant and insufficient acknowledgement of nasal immune system limits the development of vaccine. P1, a conserved region of gp41 envelope glycoprotein, was recently developed into a prophylactic HIV-1 vaccine immunized via both the intramuscular and intranasal routes. It showed high efficiency in pre-clinical and phase I clinical trial due to induction of P1 specific mucosal IgA with transcytosis blocking activity and IgG inducing antibody dependent cell cytotoxicity. In this study, we characterized the immunological mechanism underneath P1-vaccine in nasal mucosa. Firstly, we demonstrated that P1 initiate immune responses by inducing nasal epithelial cells to secret the Th2 cytokine Thymic Stromal LymphoPoietin (TSLP). TSLP has been reported to be a strong mucosal adjuvant, and its receptor TSLP-R plays a critical role in IgA response. We showed that P1 induce TSLP expression via the interaction with galactosyl ceramide, the receptor of HIV-1 mucosal entry. Furthermore, we identified Calcineurin/NFAT signaling pathway and microRNA-4485 as important players in the regulation of TSLP production induced by P1. Secondly, we showed that P1 modulates innate immune responses by activate dendritic cells (DCs). P1 stimulation results in enhanced expression of costimulatory molecules on DCs. Furthermore, the secretion of IL-6, IL-10 were increased, while IFN-γ was reduced, indicating that P1 activated DCs polarize into a Th2 and IgA prone phenotype. In addition, IL-8, CCL20, CCL22 were produced indicating a capacity at recruiting immune cells to mucosal surface for initiation of an adaptive immune response. MMP-9 was also produced allowing degradation of the extracellular matrix and facilitating the migration of immune cells out of the mucosa. Stricingly, a TSLP autocrine loop was observed as P1 induced DCs to secret TSLP and meanwhile, enhanced DC expression of TSLP-R. Finally, P1 activated DCs enhanced the proliferation of CD4+ T cells. In conclusion, we demonstrated that P1 is a multi-functional protein with a great interest for vaccine development, not only as an antigen for vaccine candidate, but also as a potential adjuvant that can be combined to other mucosal vaccines
Brinckmann, Sarah Anna. "Polyethyleneimine as a candidate vaccine adjuvant for Env-based HIV-1 infection." Thesis, University of Oxford, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.559758.
Full textBridge, Simon Harwood. "HIV-Neutralising response to recombinant, cross-clade, adjuvanted, VLP-forming vaccine candidates." Thesis, University of Liverpool, 2007. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.485898.
Full textKhodami, Pantea. "An evaluation of novel lipid-enveloped nanoparticles for adjuvant and antigen delivery for an HIV vaccine : stepping from laboratory into potential markets." Thesis, Massachusetts Institute of Technology, 2011. http://hdl.handle.net/1721.1/62742.
Full text"February 2011." Cataloged from PDF version of thesis.
Includes bibliographical references (p. 69-80).
Enormous effort has been devoted to the development of a vaccine against human immunodeficiency virus (HIV). The purpose of this paper is to evaluate the technological and economical aspects of a potential vaccine designed by Professor Irvine's group. Lipid-enveloped virion-sized nano-particles with a biodegradable polymer core are used as synthetic pathogens to deliver HIV specific antigens and adjuvants. The nano-particles are designed to display multiple copies of the antigen on their surfaces and to elicit humoral immunity response. Topics such as patent ability, obtaining an FDA licensure, storage, cost of manufacturing, and supply of the vaccine are explored. A business model for commercialization of the vaccine is outlined, and some possible future business opportunities for the nano-particles are discussed.
by Pantea Khodami.
M.Eng.
Smith, Jeffrey D. "Vaccination of BALB/c Mice with an Alhydrogel Adjuvanted Whole Cell Trichomonas vaginalis Formulation." Thèse, Université d'Ottawa / University of Ottawa, 2014. http://hdl.handle.net/10393/30424.
Full textBooks on the topic "HIV vaccine; adjuvants"
International, Symposium on the Immunobiology of Proteins and Peptides (6th 1990 Scottsdale Ariz ). Immunobiology of proteins and peptides VI: Human immunodeficiency virus, antibody immunoconjugates, bacterial vaccines, and immunomodulators. New York: Plenum Press, 1991.
Find full textImmunobiology of Proteins and Peptides VI: Human Immunodeficiency Virus, Antibody immunoconjugates, Bacterial Vaccines, Immunomodulators (Advances in Experimental Medicine and Biology). Springer, 1992.
Find full textAtassi, M. Zouhair. Immunobiology of Proteins and Peptides VI: Human Immunodeficiency Virus, Antibody Immunoconjugates, Bacterial Vaccines, and Immunomodulators. Springer London, Limited, 2012.
Find full textAtassi, M. Zouhair. Immunobiology of Proteins and Peptides Vi: "Human Immunodeficiency Virus, Antibody Immunoconjugates, Bacterial Vaccines, And Immunomodulators". Springer, 2012.
Find full textBook chapters on the topic "HIV vaccine; adjuvants"
Rizza, Paola, Imerio Capone, and Filippo Belardelli. "Adjuvants, Dendritic Cells, and Cytokines: Strategies for Enhancing Vaccine Efficacy." In The Biology of Dendritic Cells and HIV Infection, 171–202. Boston, MA: Springer US, 2007. http://dx.doi.org/10.1007/978-0-387-33785-2_5.
Full textRay, Shilpa, and Mrutyunjay Suar. "Vaccine Nanocarriers." In Handbook of Research on Diverse Applications of Nanotechnology in Biomedicine, Chemistry, and Engineering, 221–68. IGI Global, 2015. http://dx.doi.org/10.4018/978-1-4666-6363-3.ch012.
Full textRay, Shilpa, and Mrutyunjay Suar. "Vaccine Nanocarriers." In Biomedical Engineering, 1353–401. IGI Global, 2018. http://dx.doi.org/10.4018/978-1-5225-3158-6.ch058.
Full textShahid, Imran, and Qaiser Jabeen. "Appling Drug Discovery in HCV-therapeutics: A snapshot from the past and glimpse into the future." In Hepatitis C Virus-Host Interactions and Therapeutics: Current Insights and Future Perspectives, 290–342. BENTHAM SCIENCE PUBLISHERS, 2023. http://dx.doi.org/10.2174/9789815123432123010013.
Full textConference papers on the topic "HIV vaccine; adjuvants"
Farache Trajano, Luiza, Rebecca Moore, and Quentin Sattentau. "The Presence of Chemical Cross-Linking Stabilises HIV-1 Envelope Glycoprotein Trimer Antigens in a Model of Intramuscular Immunisation." In Building Bridges in Medical Science 2021. Cambridge Medicine Journal, 2021. http://dx.doi.org/10.7244/cmj.2021.03.001.4.
Full textKrishnakumar, D., and K. S. Jaganathan. "Development of nasal HPV vaccine formulations." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685403.
Full textGonçalves, Ana Katherine, Paulo César Giraldo, Kleber Juvenal Farias, Paula Renata Machado, Ana Paula Ferreira Costa, Luanda Canário De Souza, Janaina Cristiana Crispim, José Eleutério Júnior, and Steven Sol Witkin. "P1.03 Characterisation of immunoglobulin a/g responses during 3 doses of the human papillomavirus-16/18 aso4-adjuvanted vaccine." In STI and HIV World Congress Abstracts, July 9–12 2017, Rio de Janeiro, Brazil. BMJ Publishing Group Ltd, 2017. http://dx.doi.org/10.1136/sextrans-2017-053264.111.
Full textReports on the topic "HIV vaccine; adjuvants"
Pinto, Angelo J. Efficacy of the Heat-Labile Enterotoxin from Escherichia Coli as an Adjuvant for a HSV-2 Inactivated Oral Vaccine. Fort Belvoir, VA: Defense Technical Information Center, March 1996. http://dx.doi.org/10.21236/ada312064.
Full text